Live Markets »News & Advice»Market News»Market News Details
Market News Details

US FDA makes 22 observations after inspection of Lupin's Mandideep sites

Press Trust of India/New Delhi 05 Dec 18 | 01:10 PM

Drug major Lupin on Wednesday said the US health regulator has made a total of 22 observations after inspection of its facilities located at Mandideep in Madhya Pradesh.

Lupin's Mandideep location houses the company's cardiovascular Pril API facilities, Cephalosporin API facilities and Cephalosporin solid oral dosage form facility.

Related Stories

    No Related Stories Found
Widgets Magazine

These inspections were carried out between November 26 and December 4, 2018.

"The inspection at unit-2, the Cardiovascular Pril API facilities closed with 4 observations. The inspection at unit-I, the Cephalosporin facilities closed with 10 observations for the Cephalosporin API facilities and 8 observations for the Cephalosporin solid oral dosage form facility," Lupin said in regulatory filing.

Lupin said the observations are "largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalosporin API block and the company is confident of addressing them satisfactorily.

As a company, Lupin has committed to an enhanced quality management system and compliance sustainability plan. The Lupin Mandideep site is already executing the plan, which also serves to address some of the concerns raised during this inspection, the company added.

There are no new drug master file and Abbreviated New Drug Application (ANDA) pending for review or approval from Lupin's Mandideep facilities.

Shares of Lupin were trading 2.34 per cent lower at Rs 867.25 apiece on BSE.

Widgets Magazine


Company Price Gain (%)
Bajaj Fin.3,301.206.09
Hero Motocorp2,623.504.26
Maruti Suzuki6,707.203.53
Kotak Mah. Bank1,460.703.31
Bajaj Auto3,041.803.30


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine